首页> 外文期刊>International journal of clinical rheumatology. >Treating gout in patients with comorbidities
【24h】

Treating gout in patients with comorbidities

机译:在合并症患者中治疗痛风

获取原文
获取原文并翻译 | 示例
           

摘要

Gout causes extremely painful episodes of acute inflammatory arthritis, joint damage and chronic tophaceous disease. Comorbidities are common, even though their exact relationship with hyperuricemia and gout is currently uncertain. These comorbidities need to be taken into account in people who have them when treating their gout with pharmacological and nonpharmacological management, including lifestyle modification. Gout can be successfully managed in these people with consideration of the influence of medications used for gout and their impact on the components of the metabolic syndrome and on chronic renal impairment. The impact of medicines used to treat the comorbidities upon the management of acute gout, and on the requirement for reduction of uric acid to the target range of less than 6 mg/dl (0.36 mrnol/l), is also important, along with drug interactions. Although there is a shortage of randomized controlled trials to guide treatment, attention to these factors, including the incorporation of patient preferences, should lead to better adherence to therapy and improved health outcomes.
机译:痛风引起急性炎症性关节炎,关节损伤和慢性尖锐湿疣疾病的极痛苦发作。尽管目前尚不确定合并症与高尿酸血症和痛风的确切关系。在患有痛风的人进行药理和非药理学治疗(包括改变生活方式)治疗痛风时,必须考虑这些合并症。考虑到用于痛风的药物的影响及其对代谢综合征和慢性肾功能不全的影响,可以在这些人中成功治疗痛风。用于治疗合并症的药物对急性痛风的治疗以及降低尿酸至低于6 mg / dl(0.36 mrnol / l)的目标范围的要求的影响也很重要,互动。尽管缺乏指导治疗的随机对照试验,但对这些因素的关注,包括结合患者的喜好,应会导致更好地坚持治疗并改善健康状况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号